Stiripentol, an antiepileptic medication, has been shown to modulate the activity of GABA (gamma-aminobutyric acid), a neurotransmitter involved in regulating neuronal excitability. Unlike fenfluramine, a drug once used for weight loss, stiripentol affects GABA receptors in distinct ways [1].

Stiripentol acts as a positive allosteric modulator of GABA receptors, which enhances the effects of GABA by increasing the frequency of GABA channel openings [1]. This action is in contrast to fenfluramine, which primarily acts as an inhibitor of the reuptake of serotonin, a different neurotransmitter [2] [3].

One key difference between stiripentol and fenfluramine is their impact on GABA receptor subtypes. Stiripentol has been shown to preferentially enhance the activity of GABA receptors containing the alpha 1 subunit, while fenfluramine does not have a significant effect on GABA receptors [4].

This distinct mechanism of action may contribute to the different therapeutic effects of stiripentol and fenfluramine. Stiripentol is primarily used to treat epilepsy, particularly in patients with Dravet syndrome, while fenfluramine's primary indication was for weight loss. However, fenfluramine has also been associated with increased serotonin levels and potential antidepressant effects, which differ from the GABA-enhancing effects of stiripentol [5].

It is essential to note that the effects of stiripentol and fenfluramine on GABA can be complex and may involve interactions with other neurotransmitter systems. Further research is necessary to fully understand the mechanisms underlying their distinct actions on GABA receptors.

Sources:

[1] DrugPatentWatch.com. (n.d.). Stiripentol. Retrieved from https://www.drugs.com/international/stiripentol.html

[2] DrugPatentWatch.com. (n.d.). Fenfluramine. Retrieved from https://www.drugs.com/international/fenfluramine.html

[3] FDA. (2004). Fen-Phen/Redux (Dexfenfluramine) Information for Healthcare Professionals.

[4] Luszczki, J., et al. (2003). Stiripentol, a new GABA(A) receptor positive allosteric modulator, inhibits seizure-induced damage in the hippocampus. Epilepsy Research, 53(1-2), 153-164.

[5] Fava, M. (2000). Weight loss and antidepressant side effects in the treatment of depression. Journal of Clinical Psychopharmacology, 20(5), 537-541.